We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+34.92%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
+$237M
Cap. Flow
+$422M
Cap. Flow %
39.55%
Top 10 Hldgs %
35.09%
Holding
191
New
51
Increased
37
Reduced
12
Closed
55

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$32.6M
2
XHB icon
State Street SPDR S&P Homebuilders ETF
XHB
+$16.3M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$13.4M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$12.7M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$6.77M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$10.1M
2
RCKT icon
Rocket Pharmaceuticals
RCKT
+$9.16M
3
SLRN
ACELYRIN
SLRN
+$7.92M
4
PCVX icon
Vaxcyte
PCVX
+$7.26M
5
GPCR icon
Structure Therapeutics
GPCR
+$7.07M

Sector Composition

Rank Sector Weight
1 Healthcare 31.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
26
Sarepta Therapeutics
SRPT
$1.64B
$12.8M 1.2%
+132,640
New +$12.7M
IMVT icon
27
CALL
Immunovant
IMVT
$8.11B
$12.7M 1.19%
300,700
+293,470
+4,059% +$10.8M
KRYS icon
28
CALL
Krystal Biotech
KRYS
$10.8B
$12.4M 1.16%
+100,000
New +$11.1M
MLTX icon
29
PUT
MoonLake Immunotherapeutics
MLTX
$1.62B
$12.1M 1.13%
+200,600
New +$10.3M
ANNX icon
30
Annexon
ANNX
$863M
$12M 1.13%
+2,650,000
New +$6.56M
BMEA icon
31
CALL
Biomea Fusion
BMEA
$88.2M
$11.3M 1.06%
+777,600
New +$9.45M
IRON icon
32
Disc Medicine
IRON
$3.03B
$11.3M 1.05%
194,982
+52,216
+37% +$2.67M
TARS icon
33
Tarsus Pharmaceuticals
TARS
$2.6B
$10.5M 0.98%
518,519
– –
AMGN icon
34
CALL
Amgen
AMGN
$209B
$10.1M 0.94%
+35,000
New +$9.54M
IMVT icon
35
Immunovant
IMVT
$8.11B
$9.83M 0.92%
233,394
-64,400
-22% -$2.37M
SRPT icon
36
PUT
Sarepta Therapeutics
SRPT
$1.64B
$9.82M 0.92%
101,800
+98,127
+2,672% +$9.41M
ARE icon
37
PUT
Alexandria Real Estate Equities
ARE
$9.15B
$9.29M 0.87%
+73,300
New +$7.89M
ALPN
38
DELISTED
Alpine Immune Sciences Inc
ALPN
$9.29M 0.87%
+487,248
New +$6.77M
EYPT icon
39
CALL
EyePoint Inc
EYPT
$1.08B
$9.04M 0.85%
+391,000
New +$4.37M
APLS
40
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$8.98M 0.84%
150,000
+147,635
+6,242% +$7.49M
CORT icon
41
CALL
Corcept Therapeutics
CORT
$12.7B
$8.81M 0.83%
+271,300
New +$7.45M
CORT icon
42
PUT
Corcept Therapeutics
CORT
$12.7B
$8.81M 0.83%
+271,300
New +$7.45M
EYPT icon
43
EyePoint Inc
EYPT
$1.08B
$8.51M 0.8%
+368,130
New +$4.11M
CPRX
44
DELISTED
Catalyst Pharmaceutical
CPRX
$8.5M 0.8%
505,862
– –
MRNS
45
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$8.11M 0.76%
746,069
– –
DYN icon
46
CALL
Dyne Therapeutics
DYN
$4.8B
$8.08M 0.76%
607,600
+604,874
+22,189% +$5.91M
NUVL
47
CALL
DELISTED
Nuvalent
NUVL
$7.68M 0.72%
104,400
+102,005
+4,259% +$6.31M
RCUS icon
48
CALL
Arcus Biosciences
RCUS
$3.55B
$7.64M 0.72%
400,000
+396,000
+9,900% +$6.33M
PTGX icon
49
Protagonist Therapeutics
PTGX
$8.92B
$7.31M 0.68%
+319,000
New +$5.58M
BMEA icon
50
PUT
Biomea Fusion
BMEA
$88.2M
$7.26M 0.68%
+500,000
New +$6.08M
1
2
3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Ikarian Capital held 191 positions worth $1.07B, up 28% from $831M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Ikarian Capital deployed $422M of net new capital in Q4 2023, opening 51 new positions and adding to 37 existing holdings. Its largest new stake was argenx: 70,000 shares worth $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 32% a quarter earlier.

On the sell side, the largest reduction was Rocket Pharmaceuticals, an estimated $9.16M trimmed.

  • Ikarian Capital's largest Q4 2023 buy was argenx: 70,000 shares worth $26.5M.
  • Ikarian Capital added most to Disc Medicine in Q4 2023, an estimated $2.67M increase.
  • Ikarian Capital's biggest Q4 2023 reduction was Rocket Pharmaceuticals, cutting an estimated $9.16M.
  • Ikarian Capital fully exited Akero Therapeutics in Q4 2023, selling an estimated $10.1M.
  • Ikarian Capital's ten largest holdings make up 35% of its $1.07B portfolio in Q4 2023.
  • Ikarian Capital opened 51 new positions and closed 55 in Q4 2023.
  • Ikarian Capital's portfolio value rose 28% quarter-over-quarter to $1.07B.

Based on Ikarian Capital's 13F filing for Q4 2023, filed 14 Feb 2024.